Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

NCT07587515 is registered in ClinicalTrials.gov with Eyconis INC. as lead sponsor.

NCT NCT07587515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Eyconis INC.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 19, 2026
Completion date
May 31, 2028
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration